Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0348 • ACR Convergence 2021
The New EULAR/ ACR 2019 SLE Classification Criteria: A Predictor of Long-term Outcomes
Laura Whittall-Garcia¹, Dafna Gladman², Murray Urowitz³, Jiandong Su⁴, Zahi Touma⁵ and Sindhu Johnson⁶, ¹University of Toronto, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Mississauga, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: We recently demonstrated that a EULAR/ACR classification Criteria score ≥ 20 predicts a higher disease activity throughout the first 5 years after diagnosis. Given…
Abstract Number: 0531 • ACR Convergence 2021
Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Asmaa AbuMaziad¹, Abhimanyu Amarnani² and Ram Singh³, ¹University of California Los Angeles, Los Angeles, CA, ²Los Angeles County + University of Southern California, Los Angeles, CA, ³University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
Abstract Number: 0623 • ACR Convergence 2021
Intervention to Improve SLE Medication Adherence
Kai Sun¹, Amanda Eudy², Jennifer Rogers¹, Rebecca Sadun², Lisa Criscione-Schreiber¹, Jayanth Doss², Mithu Maheswaranathan¹, Ann Barr², Lena Eder³, Amy Corneli¹, Hayden Bosworth² and Megan Clowse⁴, ¹Duke University School of Medicine, Durham, NC, ²Duke University, Durham, NC, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 80% among SLE patients and leads to higher morbidity, mortality, and healthcare costs. Both the under-recognition of nonadherence…
Abstract Number: 0855 • ACR Convergence 2021
Asymptomatic Coronary Artery Disease Assessed by Coronary Computed Tomography in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Claudia Mendoza-Pinto¹, Pamela Munguía-Realpozo², Karla Godinez-Bolaños², Mario García-Carrasco², Ivet Etchegaray-Morales² and Socorro Méndez-Martínez³, ¹Instituto Mexicano del Seguro Social, San Andres Cholula, Mexico, ²Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ³Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To date, the prevalence and prognosis of coronary artery disease (CAD) according to the coronary calcium score (CCS) and coronary artery calcification (CAC) using…
Abstract Number: 0872 • ACR Convergence 2021
Lack of Association Between Cognitive Test Performance and Cognitive Symptoms in Systemic Lupus Erythematosus (SLE)
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Emma Guymer¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) is reported to affect approximately 40% of SLE patients (1). Mood disorders have been associated with both cognitive symptoms and cognitive…
Abstract Number: 0889 • ACR Convergence 2021
Association of Subjective Cognitive Report Using PDQ-20 to a Neuropsychological Battery in a Cohort of SLE Patients
Ambika Gupta¹, Sindhu Johnson², Jiandong Su³, Andrea Knight⁴, Juan Diaz-Martinez⁵, Kathleen Bingham⁶, Mahta Kakvan³, Maria Tartaglia³, Lesley Ruttan⁶, Joan Wither³, May Choi⁷, Marvin Fritzler⁸, Dennisse Bonilla³, Dorcas Beaton⁹, Patricia Katz¹⁰, Robin Green³ and Zahi Touma¹, ¹University of Toronto, Mississauga, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵UHN, Toronto, ON, Canada, ⁶University of Toronto, University Health Network, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of California San Francisco, San Francisco, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to a number of neuropsychiatric manifestations including cognitive impairment (CI). Previous meta-analyses have reported the prevalence of CI…
Abstract Number: 0994 • ACR Convergence 2021
Role of SLE Associated Cytokines in Generation of Mature Neutrophils
Neelakshi R. Jog, Julia Nguyen and Judith James, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along…
Abstract Number: 1161 • ACR Convergence 2021
Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Jennifer Dollinger¹, Celline Brasil¹, Marcus Wong¹, Glen Hazlewood², Ryan Dollinger¹, Wendy Singer³, Christian Pineau⁴, Evelyne Vinet⁵, Ann Clarke², Jennifer Lee¹ and Sasha Bernatsky⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University Health Centre, Montréal, QC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Although hydroxychloroquine (HCQ) has been shown to reduce SLE flares, concerns exist regarding side effects from long-term use. Very little information is available on…
Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Shannon Grabich¹, Eilleen Farrelly², Robert Ortmann³, Michael Pollack⁴ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…
Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Goncalo Durao-Carvalho¹, Raquel Fernandez², Bethan Goulden³, Filipa Farinha⁴ and David Isenberg⁵, ¹Servico de Medicina Interna, Centro Hospitalar do Oeste – Unidade de Caldas da Rainha, Caldas da Rainha, Portugal, Caldas da Rainha, Portugal, ²Servicio de Medicina Interna, Hospital Universitario de Ourense, Ourense, Spain, ³Department of Rheumatology, University College London Hospitals, London, United Kingdom, ⁴Department of Rheumatology, University College London Hospitals and Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…
Abstract Number: 1302 • ACR Convergence 2021
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Saira Sheikh¹, Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes Garcia¹¹, Ignacio Garcia-De La Torre¹², Regina Kurrasch¹³, Sofia Fernandes¹⁴, Julia Harris¹⁵, Saima Muzaffar¹⁴, Norma Lynn Fox¹³, Andrew Liu¹⁶, Holly Quasny¹⁷ and David Roth¹³, ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Institute of Medicine, Chung Shan Medical University; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (Republic of China), ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Henry Ford Hospital, Wayne State University, Detroit, MI, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ¹³GlaxoSmithKline, Collegeville, PA, ¹⁴GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ¹⁵GlaxoSmithKline, Uxbridge, United Kingdom, ¹⁶GlaxoSmithKline, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab (BEL) is a recombinant IgG1λ monoclonal antibody that is approved for treatment of systemic lupus erythematosus (SLE). Although clinical studies of BEL have…
Abstract Number: 1463 • ACR Convergence 2021
Use of Telemedicine for Follow-up of Lupus Nephritis in the COVID-19 Outbreak: The 6-month Results of a Randomized Controlled Trial
ho SO¹, Evelyn Chow¹, Isaac Cheng¹, Xerox Lau¹, Tena Li¹, Cheuk Chun Szeto¹ and Lai-Shan Tam², ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Telemedicine (TM) has been widely advocated and used to follow up patients with rheumatic diseases during the COVID-19 outbreak. However, there is no evidence…
Abstract Number: 1496 • ACR Convergence 2021
A Metagenome-wide Association Study Revealed Disease-specific Landscape of the Gut Microbiome of Systemic Lupus Erythematosus in Japanese
Yoshihiko Tomofuji¹, Yuichi Maeda², Eri Oguro-Igashira², Toshihiro Kishikawa¹, Kenichi Yamamoto¹, Kyuto Sonehara¹, Daisuke Motooka³, Yuki Matsumoto³, Hidetoshi Matsuoka⁴, Maiko Yoshimura⁴, Mayu Yagita², Takuro Nii², Shiro Ohshima⁵, Shota Nakamura³, Hidenori Inohara⁶, Kiyoshi Takeda⁷, Atsushi Kumanogoh² and Yukinori Okada¹, ¹Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan, ²Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, ³Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Suita, Japan, ⁴Rheumatology and Allergology, NHO Osaka Minami Medical Center, Kawachinagano, Japan, ⁵Rheumatology and Allergology, NHO Osaka Minami Medical Center, Suita, Japan, ⁶Department of Otorhinolaryngology - Head and Neck Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁷Laboratory of Immune Regulation, Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Suita, Japan
Background/Purpose: Alteration of the gut microbiome has been linked to the pathogenesis of systemic lupus erythematosus (SLE). However, a comprehensive view of the gut microbiome…
Abstract Number: 1621 • ACR Convergence 2021
Self-reported Transition Readiness of Adolescent Patients with Rheumatologic Disease: Do the Parents Agree?
Christina Ma¹, Molly Dushnicky¹, Habeba Talaat¹, Steffy Thomas¹, Karen Beattie¹, Tania Cellucci², Stephanie Garner¹, Liane Heale¹, Mark Matsos¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity. The parent-child relationship is a significant relationship in…
Abstract Number: 1734 • ACR Convergence 2021
Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
Nadia Tchao¹, Hamid Amouzadeh², Nandita Sarkar¹, Vincent Chow², Xuguang Hu¹, Mark Kroenke², Hui Wang², Rong Zhang², Kevin Gorski¹, Richard Furie³, Alan Kivitz⁴ and Stanley Cohen⁵, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].